Annals of Oncology 13:1699-1716, 2002
© 2002 European Society for Medical Oncology
Review Article |
DNA methyltransferase inhibitors—state of the art
National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, Canada
Received 1 March 2002; revised 7 June 2002; accepted 11 June 2002
Abstract
Background:
DNA methylation is the addition of a methyl group to the 5 position of cytosine. It is an epigenetic process with several effects, including chromatin structure modulation, transcriptional repression and the suppression of transposable elements. In malignancy, methylation patterns change, resulting in global hypomethylation with regional hypermethylation. This can lead to genetic instability and the repression of tumor suppressor genes.
Design:
A review of the DNA methyltransferase inhibitor literature was conducted.
Results:
DNA methylation inhibitors have demonstrated the ability to inhibit hypermethylation, restore suppressor gene expression and exert antitumor effects in in vitro and in vivo laboratory models. Four inhibitors, which are analogs of the nucleoside deoxycitidine, have been clinically tested: 5-azacytidine, 5-aza-2'-deoxycytidine, 1-ß-D-arabinofuranosyl-5-azacytosine and dihydro-5-azacytidine. The first two have demonstrated encouraging antileukemic activity but little activity in solid tumors, while the latter two are no longer under study due to lack of efficacy. A fifth agent, MG98, is an antisense oligodeoxynucleotide directed against the 3' untranslated region of the DNA methyltransferase-1 enzyme mRNA, and is now under phase II study.
Conclusions:
While some positive clinical results with DNA methyltransferase inhibitors have been seen, a definitive clinical role for these agents will most likely require combination therapy, and good phase III studies are needed.
Key words: DNA methylation, DNA methyltransferase antagonists, oligodeoxynucleotides, tumor suppressor genes
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Plummer, L. Vidal, M. Griffin, M. Lesley, J. de Bono, S. Coulthard, J. Sludden, L. L. Siu, E. X. Chen, A. M. Oza, et al. Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2009; 15(9): 3177 - 3183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thangaraju, G. A. Cresci, K. Liu, S. Ananth, J. P. Gnanaprakasam, D. D. Browning, J. D. Mellinger, S. B. Smith, G. J. Digby, N. A. Lambert, et al. GPR109A Is a G-protein-Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon Cancer Res., April 1, 2009; 69(7): 2826 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Braiteh, A. O. Soriano, G. Garcia-Manero, D. Hong, M. M. Johnson, L. D. P. Silva, H. Yang, S. Alexander, J. Wolff, and R. Kurzrock Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers Clin. Cancer Res., October 1, 2008; 14(19): 6296 - 6301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, X. Zhong, J. M. Fan, Y. J. Zhang, X. R. Liu, and X. Y. Ma External suppression causes the low expression of the Cosmc gene in IgA nephropathy Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1608 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Soriano, H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W. G. Wierda, S. Ouzounian, A. Quezada, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood, October 1, 2007; 110(7): 2302 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ishiguro, S. Iida, H. Uetake, S. Morita, H. Makino, K. Kato, Y. Takagi, M. Enomoto, and K. Sugihara Effect of Combined Therapy With Low-Dose 5-Aza-2'-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15 Ann. Surg. Oncol., May 1, 2007; 14(5): 1752 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katoh, T. Shibata, A. Kokubu, H. Ojima, M. Fukayama, Y. Kanai, and S. Hirohashi Epigenetic Instability and Chromosomal Instability in Hepatocellular Carcinoma Am. J. Pathol., April 1, 2006; 168(4): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Noh, E. R. Jang, G. Jeong, Y. M. Lee, C. K. Min, and J.-S. Lee Methyl CpG-Binding Domain Protein 3 Mediates Cancer-Selective Cytotoxicity by Histone Deacetylase Inhibitors via Differential Transcriptional Reprogramming in Lung Cancer Cells Cancer Res., December 15, 2005; 65(24): 11400 - 11410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Balch, P. Yan, T. Craft, S. Young, D. G. Skalnik, T. H-M. Huang, and K. P. Nephew Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer Mol. Cancer Ther., October 1, 2005; 4(10): 1505 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Kuykendall 5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders Ann. Pharmacother., October 1, 2005; 39(10): 1700 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fan, E.-i. Kodama, Y. Koh, M. Nakao, and M. Matsuoka Halogenated Thymidine Analogues Restore the Expression of Silenced Genes without Demethylation Cancer Res., August 1, 2005; 65(15): 6927 - 6933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Holleran, R. A. Parise, E. Joseph, J. L. Eiseman, J. M. Covey, E. R. Glaze, A. V. Lyubimov, Y.-F. Chen, D. Z. D'Argenio, and M. J. Egorin Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine Clin. Cancer Res., May 15, 2005; 11(10): 3862 - 3868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Frey Methylation of CpG islands: potential relevance for hypertension and kidney diseases Nephrol. Dial. Transplant., May 1, 2005; 20(5): 868 - 869. [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Yoo and P. A. Jones DNA Methyltransferase Inhibitors in Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 333 - 337. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rusovici, Y. Y. Hui, and H. A. LaVoie Epidermal Growth Factor-Mediated Inhibition of Follicle-Stimulating Hormone-Stimulated StAR Gene Expression in Porcine Granulosa Cells Is Associated with Reduced Histone H3 Acetylation Biol Reprod, April 1, 2005; 72(4): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Mongan and L. J. Gudas Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR{beta}2 in breast cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 477 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Das and R. Singal DNA Methylation and Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Do and H. R. Scholer Nuclei of Embryonic Stem Cells Reprogram Somatic Cells Stem Cells, November 1, 2004; 22(6): 941 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Alleman, R. L. Tabios, G. V. R. Chandramouli, O. N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rodgers, N. A. Sopko, W. M. Linehan, and J. R. Vasselli The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2'-deoxycytidine Clin. Cancer Res., October 15, 2004; 10(20): 7011 - 7021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoek, D. L. Rimm, K. R. Williams, H. Zhao, S. Ariyan, A. Lin, H. M. Kluger, A. J. Berger, E. Cheng, E. S. Trombetta, et al. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas Cancer Res., August 1, 2004; 64(15): 5270 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pakneshan, M. Szyf, R. Farias-Eisner, and S. A. Rabbani Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis J. Biol. Chem., July 23, 2004; 279(30): 31735 - 31744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pompeia, D. R. Hodge, C. Plass, Y.-Z. Wu, V. E. Marquez, J. A. Kelley, and W. L. Farrar Microarray Analysis of Epigenetic Silencing of Gene Expression in the KAS-6/1 Multiple Myeloma Cell Line Cancer Res., May 15, 2004; 64(10): 3465 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Dowell and J. D. Minna Cancer Chemotherapy Targeted at Reactivating the Expression of Epigenetically Inactivated Genes J. Clin. Oncol., April 15, 2004; 22(8): 1353 - 1355. [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, F. Arduini, A. Ruzzo, I. Bearzi, B. Humar, H. More, R. Silva, P. Muretto, P. Guilford, E. Testa, et al. Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2784 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Zhu, T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, et al. 5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation J. Biol. Chem., April 9, 2004; 279(15): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Graziano, F. Arduini, A. Ruzzo, A. Mandolesi, I. Bearzi, R. Silva, P. Muretto, E. Testa, D. Mari, M. Magnani, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs Ann. Onc., March 1, 2004; 15(3): 489 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano, B. Humar, and P. Guilford The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice Ann. Onc., December 1, 2003; 14(12): 1705 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Stewart, R. C. Donehower, E. A. Eisenhauer, N. Wainman, A. K. Shah, C. Bonfils, A. R. MacLeod, J. M. Besterman, and G. K. Reid A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Ann. Onc., May 1, 2003; 14(5): 766 - 774. [Abstract] [Full Text] [PDF]
|
|